Trial Profile
A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Estradiol (Primary)
- Indications Atrophic vaginitis
- Focus Registrational; Therapeutic Use
- Sponsors Warner Chilcott
- 11 Apr 2022 The primary endpoint Change From Baseline in the Percentage of Vaginal Parabasal Cells to Final Assessment was added, according to ClinicalTrials.gov record.
- 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.